286 related articles for article (PubMed ID: 22739699)
1. Recommendations for raloxifene use in daily clinical practice in the Swiss setting.
Lippuner K; Buchard PA; De Geyter C; Imthurn B; Lamy O; Litschgi M; Luzuy F; Schiessl K; Stute P; Birkhäuser M
Eur Spine J; 2012 Dec; 21(12):2407-17. PubMed ID: 22739699
[TBL] [Abstract][Full Text] [Related]
2. Raloxifene: a review of its use in postmenopausal osteoporosis.
Clemett D; Spencer CM
Drugs; 2000 Aug; 60(2):379-411. PubMed ID: 10983739
[TBL] [Abstract][Full Text] [Related]
3. Raloxifene: a review of its use in the prevention of invasive breast cancer.
Moen MD; Keating GM
Drugs; 2008; 68(14):2059-83. PubMed ID: 18778124
[TBL] [Abstract][Full Text] [Related]
4. Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Multiple outcomes of raloxifene evaluation.
Cauley JA; Norton L; Lippman ME; Eckert S; Krueger KA; Purdie DW; Farrerons J; Karasik A; Mellstrom D; Ng KW; Stepan JJ; Powles TJ; Morrow M; Costa A; Silfen SL; Walls EL; Schmitt H; Muchmore DB; Jordan VC; Ste-Marie LG
Breast Cancer Res Treat; 2001 Jan; 65(2):125-34. PubMed ID: 11261828
[TBL] [Abstract][Full Text] [Related]
5. Treatment of osteoporosis and reduction in risk of invasive breast cancer in postmenopausal women with raloxifene.
Ko SS; Jordan VC
Expert Opin Pharmacother; 2011 Mar; 12(4):657-74. PubMed ID: 21294695
[TBL] [Abstract][Full Text] [Related]
6. Relationship between bone mass, invasive breast cancer incidence and raloxifene therapy in postmenopausal women with low bone mass or osteoporosis.
Burshell AL; Song J; Dowsett SA; Mershon JL; Delmas PD; Secrest RJ; Cauley JA
Curr Med Res Opin; 2008 Mar; 24(3):807-13. PubMed ID: 18254988
[TBL] [Abstract][Full Text] [Related]
7. Benefit-risk assessment of raloxifene in postmenopausal osteoporosis.
Cranney A; Adachi JD
Drug Saf; 2005; 28(8):721-30. PubMed ID: 16048357
[TBL] [Abstract][Full Text] [Related]
8. Selective estrogen-receptor modulators.
Cosman F
Clin Geriatr Med; 2003 May; 19(2):371-9. PubMed ID: 12916292
[TBL] [Abstract][Full Text] [Related]
9. Effect of raloxifene combined with monofluorophosphate as compared with monofluorophosphate alone in postmenopausal women with low bone mass: a randomized, controlled trial.
Reginster JY; Felsenberg D; Pavo I; Stepan J; Payer J; Resch H; Glüer CC; Mühlenbacher D; Quail D; Schmitt H; Nickelsen T
Osteoporos Int; 2003 Sep; 14(9):741-9. PubMed ID: 12827224
[TBL] [Abstract][Full Text] [Related]
10. Raloxifene for older women: a review of the literature.
Hansdóttir H
Clin Interv Aging; 2008; 3(1):45-50. PubMed ID: 18488877
[TBL] [Abstract][Full Text] [Related]
11. [Which is the better choice, estrogen or SERMs in postmenopausal women?].
Shintani M
Clin Calcium; 2004 Oct; 14(10):105-10. PubMed ID: 15577140
[TBL] [Abstract][Full Text] [Related]
12. Reduced incidence of invasive breast cancer with raloxifene among women at increased coronary risk.
Grady D; Cauley JA; Geiger MJ; Kornitzer M; Mosca L; Collins P; Wenger NK; Song J; Mershon J; Barrett-Connor E;
J Natl Cancer Inst; 2008 Jun; 100(12):854-61. PubMed ID: 18544744
[TBL] [Abstract][Full Text] [Related]
13. Prevention and treatment of osteoporosis in women with breast cancer.
Mincey BA; Moraghan TJ; Perez EA
Mayo Clin Proc; 2000 Aug; 75(8):821-9. PubMed ID: 10943237
[TBL] [Abstract][Full Text] [Related]
14. Indicators of lifetime estrogen exposure: effect on breast cancer incidence and interaction with raloxifene therapy in the multiple outcomes of raloxifene evaluation study participants.
Lippman ME; Krueger KA; Eckert S; Sashegyi A; Walls EL; Jamal S; Cauley JA; Cummings SR
J Clin Oncol; 2001 Jun; 19(12):3111-6. PubMed ID: 11408508
[TBL] [Abstract][Full Text] [Related]
15. [Hormone replacement and selective estrogen receptor modulators (SERMS) in the prevention and treatment of postmenopausal osteoporosis].
Pfeilschifter J
Orthopade; 2001 Jul; 30(7):462-72. PubMed ID: 11515185
[TBL] [Abstract][Full Text] [Related]
16. Effect of raloxifene on bone mineral density and biochemical markers of bone turnover in Japanese postmenopausal women with osteoporosis: results from a randomized placebo-controlled trial.
Morii H; Ohashi Y; Taketani Y; Fukunaga M; Nakamura T; Itabashi A; Sarkar S; Harper K
Osteoporos Int; 2003 Oct; 14(10):793-800. PubMed ID: 12955333
[TBL] [Abstract][Full Text] [Related]
17. Design and methods of the Raloxifene Use for The Heart (RUTH) study.
Mosca L; Barrett-Connor E; Wenger NK; Collins P; Grady D; Kornitzer M; Moscarelli E; Paul S; Wright TJ; Helterbrand JD; Anderson PW
Am J Cardiol; 2001 Aug; 88(4):392-5. PubMed ID: 11545760
[TBL] [Abstract][Full Text] [Related]
18. [The role of raloxifene (Evista) in the treatment and prevention of postmenopausal osteoporosis].
Korsić M
Reumatizam; 2003; 50(2):55-7. PubMed ID: 15098379
[TBL] [Abstract][Full Text] [Related]
19. The evolution of selective estrogen receptor modulators in osteoporosis therapy.
Hadji P
Climacteric; 2012 Dec; 15(6):513-23. PubMed ID: 22853318
[TBL] [Abstract][Full Text] [Related]
20. Treatment of postmenopausal women with osteoporosis or low bone density with raloxifene. Raloxifene Study Group.
Meunier PJ; Vignot E; Garnero P; Confavreux E; Paris E; Liu-Leage S; Sarkar S; Liu T; Wong M; Draper MW
Osteoporos Int; 1999; 10(4):330-6. PubMed ID: 10692984
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
